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Pneumocystis jiroveci (human-derived P. carinii) is an opportunistic pathogenic fungus which causes pneu-
monia and is life-threatening in immunocompromised individuals. Spontaneously acquired resistance to
atovaquone, a hydroxynaphthoquinone that is used to treat P. jiroveci infections, was linked to mutations in the
mitochondrially encoded cytochrome b gene. Because P. jiroveci cannot be easily cultivated, we have developed
Saccharomyces cerevisiae as an alternative system to study atovaquone resistance mutations. In this work, we
introduced seven mutations linked with atovaquone resistance in P. jiroveci into the S. cerevisiae cytochrome b
gene. The effects of the mutations on the respiratory function and on the sensitivity to the inhibitor were then
characterized. Six of the reported mutations lowered the sensitivity of the S. cerevisiae bc1 complex to atova-
quone, while one mutation had no effect on the drug resistance. These results were confirmed by monitoring
the in vivo resistance of S. cerevisiae mutants which carried both the cytochrome b mutations and a deletion of
the ABC transporter genes, allowing the drug to bypass the weakened efflux pump system. S. cerevisiae thus
provides an easy-to-use system to characterize in vivo and in vitro cytochrome b mutations reported in
pathogens and to assess their role in drug resistance.
The mitochondrial bc1 complex is a membrane-bound en-
zyme that catalyzes the transfer of electrons from ubiquinol to
cytochrome c and couples this electron transfer to the vectorial
translocation of proton across the inner mitochondrial mem-
brane. The enzyme consists of 10 or 11 different polypeptides.
Cytochrome b, cytochrome c1, and the Rieske iron-sulfur pro-
tein form the catalytic core of the enzyme. The catalytic mech-
anism, called the Q cycle, requires two distinct quinone-bind-
ing sites (Qo, quinol oxidation site, and Qi, quinone reduction
site) which are located on opposite sides of the membrane and
linked by a transmembrane electron transfer pathway. The mito-
chondrially encoded cytochrome b provides the quinol and qui-
none binding pockets and the transmembrane electron pathway.
A number of quinol antagonists that inhibit bc1 activity are
known. They are specific for either the Qo site, such as myxo-
thiazol, stigmatellin, and strobilurin, or the Qi site, such as
antimycin, funiculosin, and diuron. Some bc1 inhibitors are
widely used in agriculture and medicine as antiparasitic drugs.
The hydroxynaphthoquinone atovaquone, for instance, is a
broad-spectrum drug active against various parasitic infections,
such as malaria, Pneumocystis jiroveci (human-derived P. cari-
nii) pneumonia, and toxoplasmosis. Resistance to the drug was
reported in Plasmodium spp. and Toxoplasma gondii isolated
from patients who experienced a recrudescence of parasitemia
after treatment with atovaquone, in parasites cultivated in vitro
on selective medium, and in animals treated with the drug (8,
10, 13). Mutations in the cytochrome b gene of the pathogens
were observed. These mutations were located in the Qo bind-
ing site pocket and correlated with an increased resistance to
atovaquone.
Several mutations in the cytochrome b gene of P. jiroveci
from AIDS patients have also been observed. P. jiroveci pneu-
monia is a common severe opportunistic infection in AIDS
patients and a significant cause of mortality. A cohort study on
AIDS patients with P. jiroveci infection suggested that expo-
sure to atovaquone increased the frequency of cytochrome b
mutations in the fungus (7). However, it is not possible to
demonstrate a direct relationship between these cytochrome b
mutations and the acquired resistance to atovaquone because
P. jiroveci cannot be cultivated in medium or isolated in suffi-
cient quantities for enzyme assay. Therefore, we developed
Saccharomyces cerevisiae as a model organism to study the
effects of the mutations observed in the fungus.
In this work, seven P. jiroveci mutations of conserved resi-
dues located in the Qo site of cytochrome b, T127I, I147V,
T148I, L150F, S152A, P266L, and L275F (Fig. 1 and 2), were
introduced into S. cerevisiae cytochrome b. The S. cerevisiae
mutants were then used to assess the effect of these mutations
on atovaquone resistance.
MATERIALS AND METHODS
Strains, media, and chemicals. The following media were used for the growth
of S. cerevisiae: YPD (1% yeast extract, 2% peptone, 3% glucose), YPG (1%
yeast extract, 2% peptone, 3% glycerol), and transformation medium (0.7% yeast
nitrogen base, 3% glucose, 2% agar, 1 M sorbitol and 0.8 g of a complete
supplement mixture minus uracil per liter, supplied by Anachem).
The following S. cerevisiae strains were used for transformation and screening:
the recipient strain for biolistic transformation was W303-1B/rho0 (MAT ura3
his3 leu2 ade2 trp1); the mit tester strains CKB78 (CYTB A144F) and CKL57
(CYTB L263Stop) were MATa leu1 kar1-1 with a rho intronless mitochondrial
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DNA. JC8/56 (MATa leu1 kar1-1 rho0) was used for cytoduction. Strains carrying
single deletions of YOR1, SNQ2, PDR5, PDR10, PDR11, YCF1, PDR3, PDR15,
and PDR1 were obtained from Euroscarf (http://www.uni-frankfurt.de/fb15/
mikro/euroscarf/). The strain AD1-9, harboring multiple deletions (MATa ura3
his1 yor1::hisG snq2::hisG pdr5::hisG pdr10::hisG pdr11::hisG ycf1::hisG
pdr3::hisG pdr15::hisG pdr1::hisG) (4) was kindly given by M. Ghislain
(UCL, Belgium). These strains were used to monitor atovaquone sensitivity in
vivo. AD1-9/rho0 was obtained by ethidium bromide treatment.
2,3-Dimethoxy-5-methyl-n-decyl-1,4-benzoquinol and myxothiazol were pur-
chased from Sigma. Stigmatellin was purchased from Fluka. Atovaquone was
obtained from Glaxo-Wellcome.
Site-directed mutagenesis, biolistic transformation, and selection of mito-
chondrial mutants. Plasmid pBM5 carrying the wild-type intronless sequence of
the CYTB gene was constructed by blunt-end cloning of a PCR product of CYTB
into the pCRscript vector (Stratagene). The mutagenesis was performed with the
Quickchange site-directed mutagenesis kit (Stratagene) according to the manu-
facturer’s recommendations. After verification of the sequence, the plasmids
carrying the mutated genes were used for biolistic transformation.
Mitochondrial transformation by microprojectile bombardment was adapted
from reference 1. Approximately 3 g of the plasmids carrying the mutated
CYTB genes and 0.5 g of plasmid YEP352 (which contains the URA3 gene,
allowing the selection of Ura nuclear transformants) were mixed with 50 l of
0.7-m tungsten particles (at a concentration of 60 mg/ml). The particles (sup-
plied by Bio-Rad) were prepared and coated with DNA according to the man-
ufacturer’s protocol. Aliquots of the coated particles were used for transforma-
tion of the recipient strain W303-1B/rho0. Around 107 cells of the recipient strain
were evenly spread on transformation medium (selective for Ura transfor-
mants). The particle bombardments were performed with a Biolistic PDS-
1000/He particle delivery system (Bio-Rad) according to the manufacturer’s
recommendations.
Colonies of Ura transformants (which have received plasmid YEP352) ap-
peared after 4 to 5 days of incubation. The Ura colonies were crossed with re-
spiratory-deficient (mit) tester strains CKB78(A144F) and CKL57(L263Stop),
which carry mutations located near the atovaquone resistance mutations (Fig. 1).
CKB78(A144F) was used for mutations in residues 127 to 152, whereas CKL57
(L263Stop) was used for mutations in residues 266 and 275. The diploids were
replica-plated on respiratory medium (YPG). Since the tester deficiency muta-
tions could be corrected by recombination with the plasmid-derived mitochon-
drial sequence, mitochondrial transformants were identified by their ability to
form respiration-competent diploids when crossed with the tester strains. Res-
piration-competent diploids that issued from the crossing were selected and
subcloned. Their sequencing showed that the new mutations were incorporated
while the tester mutations were replaced by the wild-type codon.
Construction of S. cerevisiae strains with combined atovaquone resistance
mutations and deletion of membrane transporters. The mitochondrial genome
carrying the atovaquone resistance mutations was transferred into strain AD1-9
as follows. The mitochondrial transformants which carried the atovaquone re-
sistance mutations were sporulated. The haploid clones were used for cytoduc-
tion of the mitochondrial genome into the recipient strain JC8/56 (rho0). This
strain carries the mutation kar1-1, which is required for cytoduction (3). These
cytoductants were then used to transfer the mitochondrial genome into AD1-9/
rho0. The resulting strains combined atovaquone mutations and multiple dele-
tions in the membrane transporters and were used to monitor atovaquone re-
sistance in vivo.
Preparation of mitochondrial membrane, cytochrome c reductase activity, and
inhibitor titrations. Mitochondrial membranes were isolated as described before
(12). Cytochrome c reductase activity measurements were assayed in 50 mM
potassium phosphate (pH 7.0), 250 mM sucrose, 0.2 mM EDTA, 1 mM NaN3,
2.5 mM KCN, 0.01% Tween 20, and 40 M cytochrome c (assay buffer) at 23°C.
Membranes were diluted to 2.5 nM cytochrome bc1 complex. The reaction was
started by adding 50 M 2,3-dimethoxy-5-methyl-n-decyl-1,4-benzoquinol, an
analogue of ubiquinol. Reduction of cytochrome c was monitored in an Aminco
FIG. 1. Sequence alignment of S. cerevisiae (Sc), P. jiroveci, and human-derived P. carinii (Pc) mitochondrial cytochrome b. Point mutations
discussed in this paper are boxed in bold lines. Residues in close contact with stigmatellin in the S. cerevisiae bc1 complex crystal structure 1EZV
(defining the Qo site) are indicated by a grey line above the sequence data. Residues corresponding to the tester mutations A144F and L263stop
are circled.
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DW-2a spectrophotometer at 550 versus 539 nm in dual-wavelength mode. Data
were collected and analyzed with an Online Instrument Systems Inc. computer
interface and software. Activities of the bc1 complex in membranes were mea-
sured in duplicate, and turnover numbers were calculated on the basis of cyto-
chrome b concentration. The cytochrome b content was estimated from reduced
minus oxidized spectra, with the extinction coefficient 25 mM1 cm1 at 562 to
572 nm.
Spectroscopic analysis of cytochromes in whole cells. Spectra were generated
by scanning cell suspensions with a single-beam spectrophotometer built in-
house. The cells, grown on YPG plates for 48 h, were resuspended in 5% Ficoll
at a concentration of around 200 mg of cells per ml and reduced with dithionite.
A quadratic baseline compensation was carried out on the data as described
before (2) to remove the distortion of the baseline.
RESULTS AND DISCUSSION
Generation of S. cerevisiae mutants harboring cytochrome b
mutations observed in P. jiroveci. Several mutations in the
cytochrome b gene of P. jiroveci were reported following ex-
posure to atovaquone. The mutations T127I, I147V, T148I,
L150F, S152A, P266L, and L275F (S. cerevisiae numbering) are
located in the Qo binding site (Fig. 1 and 2). Because P. jiroveci
cannot be cultivated in medium, a model organism is needed to
assess the role of the mutations in atovaquone resistance. S.
cerevisiae is the obvious choice. S. cerevisiae is amenable to
mitochondrial transformation, so that designed mutations can
be introduced in the mitochondrially encoded cytochrome b. In
addition, the sequences of cytochrome b from S. cerevisiae and
P. jiroveci are highly similar (63% identity), as shown in Fig. 1.
The P. jiroveci mutations were therefore introduced into S.
cerevisiae by the biolistic technique as described in Materials
and Methods. The effects of the mutations on respiratory com-
petence and resistance to inhibitor were then monitored.
Effect of mutations on respiratory competence. The growth
rate of the wild-type and mutant strains in respiratory medium
(YPG) was monitored. The mutations had no effect on the
respiratory competence of the cells, since the doubling times
on a nonfermentable carbon source of the control and mutant
strains were identical (5 h). Similarly, no significant decrease
in oxygen consumption was observed in the mutant cells (data
not shown). Analysis of the optical signal of the cytochromes in
whole cells showed a slight decrease in the cytochrome b con-
tent in the mutants compared with the wild-type strain. The
cytochrome b level was decreased by approximately 15% in all
the mutants except T148I, where the cytochrome b content was
decreased by approximately 30%. Figure 3 shows the optical
spectra of the wild-type strain and two mutants: T148I, which
had a low cytochrome b content, and I147V. The optical spec-
tra of the remaining mutants were almost identical to that of
I147V. Thus, it seems that the introduction of the mutations
slightly affect the folding of cytochrome b and/or the assembly
of acomplex.
Mitochondrial membranes were prepared from the wild-
FIG. 2. Location of atovaquone resistance mutations in the bc1 structure. The structure was drawn with the coordinates of the S. cerevisiae
enzyme (accession number PDB 1EZV) (6). The bound inhibitor stigmatellin is in green.
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type and mutant strains, and the ubiquinol-cytochrome c re-
ductase activity of the bc1 complex in the membranes was
monitored as described in Materials and Methods (Table 1).
The activity in the absence of inhibitor was 48 s1 for the
wild-type enzyme. The introduction of the T127I mutation had
little effect, since the activity was 81% of that of the wild type.
In I147V, T148I, L150F, P266L, and L275F, the activity was
decreased by 33 to 55%. The mutation S152A seemed to have
a more deleterious effect on the activity, since it was decreased
to 20% of that of the wild type. The decrease in the bc1 activity
was not unexpected, since the mutations affected residues in
the Qo site of the enzyme, which is essential for its catalytic
activity.
T127, I147, T148, and L150 are very highly conserved resi-
dues in mitochondrial cytochrome b. P266 and L275 are com-
pletely conserved in the available mitochondrial sequence
data. S152 is less well conserved in eukaryotes and is replaced
by another hydroxylated residue, such as tyrosine or threonine,
in some species. The S152A mutation, however, had the more
deleterious effect. The decreased activity might be explained by
the lost of the hydroxyl group of residue 152, which could
hydrogen bond with the amide side chain of N149 and stabilize
the structure. The introduction of the bulky phenyl side chain
in the L150F mutant might be expected a priori to be especially
detrimental. However, the structure seems to be able to ac-
commodate a large residue in that region, since the bc1 activity
of the mutant was still 54% of the wild-type activity.
The decrease in both cytochrome b content and bc1 activity
in the mutant cells was not enough to affect the respiratory
growth of the mutants. The introduction of these mutations
had little or no effect on the overall fitness of these strains. It
is likely that the mutations do not have severely deleterious
effects in P. jiroveci, because a major decrease in respiratory
competence would be lethal for the fungus.
Effect of mutations on sensitivity of bc1 complex to atova-
quone. In order to assess the role of the mutations on atova-
quone resistance, mitochondrial membranes were prepared
from the wild-type and mutant strains, as described above, and
the cytochrome c reductase activity was monitored in the pres-
ence of increasing concentrations of atovaquone (Fig. 4).
Atovaquone is an efficient inhibitor of the S. cerevisiae bc1
complex because the inhibitor concentration required for 50%
inhibition of the activity (I50) was around 50 nM. This was in
agreement with data obtained with other organisms and with
other methods: the concentration required for a 50% decrease
in the membrane potential in Plasmodium yoelii was 15 nM
(13), and a 50% decrease in nucleic acid synthesis activity
was observed in the presence of 20 and 50 nM atovaquone in
Plasmodium berghei and Toxoplasma gondii, respectively (14,
10).
It is likely that the atovaquone binds in the same domain of
the Qo pocket as stigmatellin. The Qo site of cytochrome b is a
rather large domain formed from components encompassing
amino acid residues 120 to 150 and 260 to 280 of the polypep-
tide chain. It consists of two lobes, a heme bl proximal lobe and
a distal lobe. The distal lobe is close to the surface region of
cytochrome b involved in interactions with the peripheral do-
main of the iron-sulfur protein. The stigmatellin head group
binds in this distal domain and is positioned in a pocket formed
by the regions from 122 to 131, 142 to 152, and 268 to 280 (Fig.
1). All interactions with the iron-sulfur protein occur in this
region. The pharmacophore side chains of myxothiazol and
monoamine oxidase-type inhibitors, by contrast, occupy the
proximal domain. Since atovaquone affects the midpoint po-
tential and electron paramagnetic resonance spectrum of the
iron-sulfur protein (T. Merbitz-Zahradnik and B. Trumpower,
unpublished observations), it is likely that atovaquone binds in
the distal domain, similar to stigmatellin.
It is interesting that the P. jiroveci mutations studied here are
located in or close to the inhibitor binding regions (Fig. 1). It
was therefore expected that they might modify the sensitivity of
the bc1 complex to atovaquone. In addition, mutations of res-
idues L275 and I147, conferring resistance to other Qo inhib-
itors in S. cerevisiae, were reported previously (5). As shown in
Fig. 4, three mutants, T148I, I147V, and L150F, showed a
slight decrease in sensitivity to atovaquone. The I50 increased
to approximately 100 to 150 nM. Three mutants, P266L, L275F,
and S152A, showed a marked resistance, with I50s higher than
FIG. 3. Optical spectra of wild-type, L148I, and L147V cells. Op-
tical spectra of reduced cell suspensions were obtained as described in
Materials and Methods. c, cytochrome c (heme c); b, cytochrome bc1
(hemes b); a, cytochrome oxidase (hemes aa3).
TABLE 1. Cytochrome c reductase activities of mitochondrial
membranes and sensitivity to atovaquone
Strain Activity (% ofwild type)a
Atovaquone
I50 (nM)b








a The cytochrome c reductase activities were measured as described in Mate-
rials and Methods.
b The I50 is the concentration of atovaquone required to obtain 50% inhibition
of the activity.
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350 nM. Surprisingly, T127I did not show any increased resis-
tance to atovaquone.
The threefold increase in resistance observed with the
L150F mutant is undoubtedly due to steric hindrance arising
from the bulky aromatic side chain of the introduced phenyl
group. Similarly, P266L and L275F, which confer high atova-
quone resistance, result in the introduction of bulkier nonpolar
side chains, which may sterically hinder antagonist binding.
I147V represents a conservative structural change. The loss of
a side chain methylene moiety may remove a potentially sta-
bilizing hydrophobic interaction with atovaquone bound at the
Qo site or may subtly affect the packing of the protein around
this region, which forms a tunnel for access to the lipid phase.
The mutations S152A and T148I both result in replacement of
a residue with a polar, hydroxylated side chain by a nonpolar,
aliphatic species, although the resistance of S152A is much
higher than that of T148I. It is possible that the mutations
abolish hydrogen bond interactions involving S152 or T148 and
result in slight structural rearrangement of components within
the Qo site. Molecular modeling studies with minimum energy
calculations to assess structural changes in the protein result-
ing from the resistance mutations are currently in progress.
Because of the high similarity between S. cerevisiae and
P. jiroveci cytochrome b, it is expected that the mutations have
similar effects on the pathogen’s bc1 complex. The mutation
T127I probably has little effect on the bc1 sensitivity to atova-
quone in P. jiroveci. As shown above, this mutation also had
little effect on the activity of the complex. It is tempting to
suggest that the change is a silent mutation. The mutations
I147V, T148I, and L150F would confer a slight advantage to
the mutant fungi when exposed to atovaquone, whereas the
mutations P266L, L275F, and S152A would cause a marked
resistance to treatment with the drug.
Sensitivity of S. cerevisiae cells to atovaquone treatment. As
shown in Fig. 4, the molecular target of atovaquone, the bc1
complex, is inhibited by submicromolar concentrations of
atovaquone. However, S. cerevisiae is naturally resistant to the
drug. At 50 M atovaquone, no decrease in respiratory growth
was observed for the control strain (Fig. 5). Since it was likely
that the resistance of the S. cerevisiae cells to atovaquone
treatment was due to efficient efflux pumps, we monitored the
sensitivity of strains harboring deletions of genes involved in
drug resistance, namely YOR1, SNQ2, PDR5, PDR10, PDR11,
YCF1, PDR3, PDR15, and PDR1. These genes are members of
gene families which, in mammalian cells, are involved in the
resistance of tumor cells to anticancer treatment. Similar
mechanisms exist in pathogenic fungi, such as Candida and
Aspergillus spp. (11, 15). PDR1 and PDR3 code for transcrip-
tional regulators. Yor1p, Snq2p, Pdr5p, Pdr10p, Pdr11p, Ycf1p,
and Pdr15p are ABC transporters (reviewed in reference 16).
These plasma membrane transporters, especially Pdr5p and
Snq2p, mediate the ATP-dependent efflux of a large number of
unrelated compounds.
As shown in Fig. 5, none of the single deletions resulted in
a dramatic increase in the sensitivity to atovaquone. Only a
slight decrease in respiratory growth was observed. By contrast,
the deletion of the nine genes in strain AD1-9 (yor1, snq2,
pdr5, pdr10, pdr11, ycf1, pdr3, pdr15, and pdr1) se-
verely increased the sensitivity of the cells to the drug. It is
therefore likely that atovaquone can be pumped out across the
plasma membrane by two or more transporters and that a clear
phenotype is observed when all the transporters involved in its
FIG. 4. Effect of atovaquone on bc1 activity of wild-type (wt) parental and mutant strains. The cytochrome c reductase activity of mitochondrial
membranes was measured as described in Materials and Methods in the presence of increasing concentrations of inhibitor. The assays were
performed in duplicate, and the results are shown as averages, with less then 10% variation in individual rates. Activities are expressed as a
percentage of the turnover number of each strain in the absence of atovaquone.
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efflux are inactivated. This was observed for other compounds.
Pdr5p and Snq2p, for example, have overlapping transport
activity for steroids (9). Yor1p and Pdr5p also share several
substrates (4). The identification of the exact mechanism caus-
ing resistance in S. cerevisiae is beyond the scope of this study
but would be interesting because the equivalent genes in P.
jiroveci and other pathogens could be involved in resistance to
atovaquone treatment.
The multiple deletion of genes involved in multidrug resis-
tance resulted in an increased sensitivity to atovaquone. The
AD1-9 strain, which combines the inactivation of the ABC
transporters and a wild-type cytochrome b, was indeed unable
to grow in the presence of atovaquone. This hypersensitive
strain could then be used to monitor in vivo the drug resistance
caused by cytochrome b mutations. For this purpose, the seven
mutant strains and a parental (wild-type) strain were con-
structed as described in Materials and Methods. They derived
from AD1-9 but harbored the P. jiroveci cytochrome b muta-
tions mentioned above. As shown in Fig. 5, T127I did not
confer any resistance to the drug, whereas the other mutations
resulted in clear resistance to the inhibitor. These data are in
agreement with the results obtained in our in vitro studies.
Such S. cerevisiae strains could be useful tools to screen new
compounds and to test the cross-resistance of existing mutants.
In conclusion, we have shown here that S. cerevisiae provides
an easy-to-use system to characterize cytochrome b mutations
observed in pathogens and to assess their role in drug resis-
tance. Since S. cerevisiae is amenable to mitochondrial trans-
formation, mutations found in cytochrome b in pathogens can
be introduced into the S. cerevisiae mitochondrial gene. In
addition, the availability of strains with multiple deletions of
membrane transporters allows the in vivo study of drug resis-
tance. The characterization of the resistance mutations in the
pathogens and in model organisms such as S. cerevisiae could
provide molecular markers to monitor the potential resistance
of pathogens and screening tools for new inhibitors.
FIG. 5. Sensitivity of S. cerevisiae cells to atovaquone exposure. The name and position of the strains tested are shown above the plates. YOR1,
YCF1, PDR3, SNQ2, PDR15, PDR10, PDR1, PDR5, and PDR11 are strains carrying single deletions of genes of the ABC transporter
family; AD1-9 carries deletions of all these genes (left-hand panels). The right-hand panels show the growth of AD1-9 and the seven strains derived
from AD1-9 which carry cytochrome b mutations. WT, wild type.
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